Anna Rivkin
Chief Business Officer Foghorn Therapeutics
Anna Rivkin, PHD joined Foghorn as Chief Business Officer (CBO) in September 2024. Before joining Foghorn, Anna most recently held leadership roles at Bristol Myers Squibb (BMS) where she successfully oversaw strategic transactions across immunology, neuroscience, and cardiovascular disease as the Vice President of Business Development. Anna helped evolve the BMS pipeline including leading high-impact deals such as the $14 billion purchase of Karuna Therapeutics and the $13 billion purchase of MyoKardia Therapeutics. Prior to BMS, Anna worked at Merck & Co., holding a number of roles of increasing responsibilities in business development and clinical research. Anna received her Ph.D. in Neuroscience from Case Western Reserve University and holds a B.A. from Johns Hopkins University.
Seminars
- Which stage of development is most appealing in Immunology?
- What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T?
- When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
- Which diseases do you think are most promising for B-cell targeted therapies?
